Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 375

Results For "LA"

9462 News Found

Govt. issues draft amendment to remove cough syrups from Schedule K
Policy | January 01, 2026

Govt. issues draft amendment to remove cough syrups from Schedule K

Once finalized, cough syrups will no longer be available for over-the-counter sale


Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery
News | January 01, 2026

Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery

The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement


Savara resubmits FDA application for potential treatment in rare lung disease patients
Biopharma | January 01, 2026

Savara resubmits FDA application for potential treatment in rare lung disease patients

The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer


Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
Clinical Trials | January 01, 2026

Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials

The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates


Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs
Biotech | January 01, 2026

Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs

The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”


SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
Clinical Trials | January 01, 2026

SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent

The study will run across 18 sites and enroll roughly 200 patients over 24 months


Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency
News | January 01, 2026

Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

The accelerated review covers WCK 5222 for multiple critical infections


Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
News | January 01, 2026

Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics

The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease


HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
News | January 01, 2026

HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer

ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium


CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers
Clinical Trials | December 31, 2025

CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers

The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively